Current challenges in peptide-based drug discovery

Frontiers in Chemistry

Volumn 2, Issue AUG, 2014, Pages

  Otvos, Laszlo ^a   Wade, John D ^b  

^a Temple University   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Grand challenges; Oral delivery; Peptide drug development; Peptides; Pharmacodynamics; Pharmacokinetics

Indexed keywords

EID: 84987608654     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00062     Document Type: Article

References (44)

1. Albert, R., Marbach, P., Bauer, W., Briner, U., Fricker, G., Bruns, C., et al. (1993). SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. Life Sci. 53, 517-525. doi: 10.1016/0024-3205(93)90703-6
2. Appella, E., Padlan, E. A., and Hunt, D. F. (1995). Analysis of the structure of naturally processed peptides bound by class I and class II major histocompatibility complex molecules. Experimentia 73, 105-119.
3. Atkinson, T. (2002). Lifestyle drug market booming. Nat. Med. 8, 909. doi: 10.1038/nm0902-909
4. Boylan, N. J., Zhou, W., Proos, R. J., Tolbert, T. J., Wolfe, J. L., and Laurence, J. S. (2013). Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates. Bioconjug. Chem. 24, 1008-1016. doi: 10.1021/bc4000564
5. Carton, J. M., and Strohl, W. R. (2013). "Protein therapeutics (Introduction to biopharmaceuticals), " in Biological and Small Molecule Drug Research and Development, eds R. Ganelin, R. Jefferts, and S. Roberts (Waltham, MA: Academic Press), 127-159.
6. Charlton, S. T., Whetstone, J., Fayinka, S. T., Read, K. D., Illum, L., and Davis, S. S. (2008). Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm. Res. 25, 1531-1543. doi: 10.1007/s11095-008-9550-2
7. Cudic, M., Condie, B. A., Weiner, D. J., Lysenko, E. S., Xiang, Z. Q., Insug, O., et al. (2002). Development of novel antibacterial peptides that kill resistant isolates. Peptides 23, 2071-2083. doi: 10.1016/S0196-9781(02)00244-9
8. Demchyshyn, L. L., McConkey, F., and Niznik, H. B. (2000). Dopamine D5 receptor agonist high affinity and constitutive activity profile conferred by carboxy-terminal tail sequence. J. Biol. Chem. 275, 23446-23455. doi: 10.1074/jbc.M000157200
9. Dooley, C. T., and Houghten, R. A. (1993). The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands. Life Sci. 52, 1509-1517. doi: 10.1016/0024-3205(93)90113-H
10. Egleton, R. D., and Davis, T. P. (2005). Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx. 2, 44-53. doi: 10.1602/neurorx.2.1.44
11. Ertl, H. C., Dietzschold, B., and Otvos, L. Jr. (1991). T helper cell epitope of rabies virus nucleoprotein defined by tri-and tetrapeptides. Eur. J. Immunol. 21, 1-10. doi: 10.1002/eji.1830210102
12. Fasano, A. (1998). Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 16, 152-157. doi: 10.1016/S0167-7799(97)01170-0
13. Gentilucci, L., De Marco, R., and Cerisoli, L. (2010). Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 16, 3185-3203. doi: 10.2174/138161210793292555
14. Gupta, V., Hwang, B. H., Lee, J., Anselmo, A. C., Doshi, N., and Mitragotri, S. (2013). Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. J. Control. Release. 172, 753-762. doi: 10.1016/j.jconrel.2013.09.004
15. Hay, M., Thomas, D. W., Craighead, L., Economides, C., and Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51. doi: 10.1038/nbt.2786
16. Hruby, V. J. (2002). Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 1, 847-858. doi: 10.1038/nrd939
17. Kaspar, A. A., and Reichert, J. M. (2013). Future directions for peptide therapeutics development. Drug Discov. Today 18, 807-817. doi: 10.1016/j.drudis.2013.05.011
18. Khazanov, N. A., and Carlson, H. A. (2013). Exploring the composition of protein-ligand binding sites on a large scale. PLoS Comput. Biol. 9:e1003321. doi: 10.1371/journal.pcbi.1003321
19. Kihlberg, J., Ahman, J., Walse, B., Drakenberg, T., Nilsson, A., Söderberg-Ahlm, C., et al. (1995). Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of (1-desamino, 8-D-arginine) vasopressin. J. Med. Chem. 38, 161-169. doi: 10.1021/jm00001a021
20. Kovalszky, I., Surmacz, E., Scolaro, L., Cassone, M., Sztodola, A., Olah, J., et al. (2010). Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models. Diabetes Obes. Metab. 12, 393-402. doi: 10.1111/j.1463-1326.2009.01170.x
21. Li, Z. J., and Cho, C. H. (2012). Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J. Transl. Med. 10, 51. doi: 10.1186/1479-5876-10-S1-S1
22. Maggio, E. T. (2006). Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv. 3, 529-539. doi: 10.1517/17425247.3.4.529
23. Noto, P. B., Abbadessa, G., Cassone, M., Mateo, G. D., Agelan, A., Wade, J. D., et al. (2008). Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17, 1249-1255. doi: 10.1110/ps.034330.108
24. Otvos, L. Jr. (2014a). Peptide-based drug research and development: relative costs, comparative value. Pharm. Outsourc. 15, 16-20. Available online at: http://www.pharmoutsourcing.com/Featured-Articles/161800-Peptide-based-Drug-Research-and-Development-Relative-Costs-Comparative-Value/
25. Otvos, L. Jr. (2014b). Peptide-based drug discovery and development. Common misconceptions. Pharm. Outsourc. 15, 40-43. Available online at: http://www.pharmoutsourcing.com/Featured-Articles/157959-Peptide-based-Drug-Discovery-Development/
26. Otvos, L. Jr. Haspinger, E., La Russa, F., Maspero, F., Graziano, P., Kovalszky, I., et al. (2011a). Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol. 11:90. doi: 10.1186/1472-6750-11-90
27. Otvos, L. Jr. Kovalszky, I., Riolfi, M., Ferla, R., Olah, J., Sztodola, A., et al. (2011c). Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. Eur. J. Cancer 47, 1578-1584. doi: 10.1016/j.ejca.2011.01.018
28. Otvos, L. Jr. Kovalszky, I., Scolaro, L., Sztodola, A., Olah, J., Cassone, M., et al. (2011b). Peptide-based receptor antagonists for cancer treatment and appetite regulation. Biopolymers 96, 117-125. doi: 10.1002/bip.21377
29. Otvos, L. Jr. Shao, W.-H., Vanniasinghe, A., Amon, M. A., Holub, M. C., Kovalszky, I., et al. (2011d). Towards understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides 32, 1567-1574. doi: 10.1016/j.peptides.2011.06.015
30. Otvos, L. Jr. Terrasi, M., Cascio, S., Cassone, M., Abbadessa, G., Di Pascali, F., et al. (2008). Development of a pharmacologically improved peptide agonist of the leptin receptor. Biochim. Biophys. Acta 1783, 1745-1754. doi: 10.1016/j.bbamcr.2008.05.007
31. Otvos, L. Jr. Vetter, S. W., Koladia, M., Knappe, D., Schmidt, R., Ostorhazi, E., et al. (2014). The designer leptin antagonist peptide Allo-aca compensates for short serum half-life with very tight binding to the receptor. Amino Acids 46, 873-882. doi: 10.1007/s00726-013-1650-6
32. Powell, M. F., Grey, H., Gaeta, F., Sette, A., and Colon, S. M. (1992). Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharm. Sci. 81, 731-735. doi: 10.1002/jps.2600810802
33. Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008). Dose translation from animal to human studies revisited. FASEB J. 22, 569-661. doi: 10.1096/fj.07-9574LSF
34. Romero, E., Velez de Mendizabal, N., Cendros, J. M., Peraire, C., Bascompta, E., Obach, R., et al. (2012). Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer. J. Pharmacol. Exp. Ther. 342, 788-798. doi: 10.1124/jpet.112.195560
35. Sachdeva, V., Zhou, Y., and Banga, A. K. (2013). In vivo transdermal delivery of leuprolide using microneedles and iontophoresis. Curr. Pharm. Biotechnol. 14, 180-193. doi: 10.2174/1389201011314020008
36. 037, a novel parenteral broad-spectrum cephalosporin. J. Antibiot. 46, 120-130. doi: 10.7164/antibiotics.46.120
37. Shimizu, M., Carter, P. H., Khatri, A., Potts, J. T. Jr., and Gardella, T. J. (2001). Enhanced activity in parathyroid hormone-(1-14) and-(1-11): novel peptides for probing ligand-receptor interactions. Endocrinology 142, 3068-3074. doi: 10.1210/en.142.7.3068
38. Sillerud, L. O., and Larson, R. S. (2005). Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr. Protein Pept. Sci. 6, 151-169. doi: 10.2174/1389203053545462
39. Teesalu, T., Sugahara, K. N., Kotamraju, V. R., and Ruoslahti, E. (2009). C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. U.S.A. 106, 16157-16162. doi: 10.1073/pnas.0908201106
40. Thomas, D. (2013). A big year for novel drug approvals. BIOtechNOW. Available online at: http://www.biotech-now.org/business-and-investments/inside-bio-ia/2013/01/a-big-year-for-novel-drugs-approvals#
41. Varamini, P., Mansfeld, F. M., Blanchfield, J. T., Wyse, B. D., Smith, M. T., and Toth, I. (2012). Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J. Med. Chem. 55, 5859-5867. doi: 10.1021/jm300418d
42. Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., and Rothbard, J. B. (2000). The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 97, 13003-13008. doi: 10.1073/pnas.97.24.13003
43. Yan, Z., and Wang, J. (2012). Specificity quantification of biomolecular recognition and its implication for drug discovery. Sci. Rep. 2:309. doi: 10.1038/srep00309
44. Zannikos, P. N., Rohatagi, S., Jensen, B. K., DePhillips, S. L., and Rhodes, G. R. (2000). Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J. Clin. Pharmacol. 40, 1129-1140. doi: 10.1177/009127000004001007